Maternal and foetal care has become an important concern in the wake of enormous global spread of coronavirus disease-2019 (COVID-19), but there is scarcity of information about maternal and perinatal outcomes. The current review was conducted from March to July 2020. Appropriate and related databases were searched electronically by using terms, like "COVID-19 and pregnancy", "pregnancy outcomes of COVID-19". Pooled analysis of the reviewed studies showed that of the 164 newborns, vertical transmission was noted in 7(2.95%). The most common element 140(84.98%) was caesarean section deliveries. COVID-19 pneumonia developed in almost 54(30.90%) of 175 women. The most common symptom of COVID-19 among women was fever 88(50.77%). Adverse maternal and foetal outcomes were found to be associated with COVID-19 in the form of severe illness, increased rates of caesarean section deliveries and worse birth outcomes. Yet, vertical transmission of COVID-19 infection remains debatable.
Keywords: COVID-19, Maternal outcomes, Perinatal outcomes.
In the Chinese city of Wuhan, a series of patients presented with pneumonia of unknown cause in December 2019. The clinical signs and symptoms were different from bacterial pneumonia and resembled viral infection.1 Gene sequencing analysis of samples taken from the respiratory tract of the infected patients showed that novel coronavirus was the causal agent of the infection.2 The virus that causes the novel coronavirus disease-2019 (COVID-19) was designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).3
There is a rapid spread of the viru from China to almost all parts of the world since December 2019. In March 2020, the World Health Organisation (WHO) declared COVID-19 a global pandemic.4 By October 28, 2020, COVID-19 had become global public health emergency of critical concern with 43,965,951 global cases and 1,166,908 global deaths.5
In the management of any infectious disease, care and protection of vulnerable populations is the key element. Pregnant women and their foetuses comprise a vulnerable group during pandemics of infectious disease. As the number of cases are globally on the rise at an exponential rate, facts on incidence, transmission and effect of COVID-19 in pregnant women and their newborns remain inadequate. Pregnant women are reported to be disproportionately affected by respiratory diseases, which are associated with high maternal mortality and infectious morbidity rates. Pregnant women compared to the general population are supposed to be more prone to getting this infection.6 Besides, they may be more vulnerable to severe infection because of changes to the immune system.7
Facts from other similar viral diseases, such as influenza "A/H1N1",8-11 SARS12 and Middle East respiratory syndrome (MERS),13 showed that these women are at a higher risk of severe maternal and neonatal mortality and morbidity. Evidence supports that in the later terms of pregnancy, the risk of critical illness may be increased.8,14
MERS Coronavirus (MERS-CoV) and SARS-CoV share similarities with SARS-CoV-2 as they are beta (b) coronaviruses having somewhat identical genomic structures.15 In SARS epidemic, 8,098 cases were reported and its case fatality rate was about 10.5%3 whereas in the MERS epidemic, 2,519 individuals got infected and case fatality rate was around 34.4%.16 Importantly, SARS-CoV and MERS-CoV have also been considered the cause of maternal morbidity and mortality.12,14 In the recent pandemic caused by SARS-CoV-2, the extent of adverse maternal and perinatal outcomes are still unclear.
The current narrative review was planned to assess the extent of adverse maternal and perinatal outcomes of COVID-19 throughout the first wave of COVID-19.
The current review was conducted from March to July 2020. Relevant databases, like Google Scholar, PubMed, Scopus, Embase and Medline, were searched by using relevant terms, like "COVID-19 and pregnancy", "pregnancy outcomes of COVID-19". Articles included were mostly retrospective studies, case reports and case series because limited data was available at the time of conducting the review.
Studies included were related to pregnant women having confirmed COVID-19 infection by reverse transcription polymerase chain reaction (RT-PCR). Studies having data about newborns but missing evidence about pregnancy and maternal outcomes were excluded.
The outcomes were divided into three main headings; General health of pregnant women, terminations of pregnancy/Mode of delivery and complications; and foetal outcomes.
All titles, summaries and abstracts were reviewed independently by three researchers for relevance and inclusion in the review. In case of disagreement, the matter was resolved by discussion. Requisite data regarding COVID-19 symptoms, maternal and perinatal outcomes was mined by the same researchers.
At first, general health of confirmed COVID-19 pregnant women was analysed to assesses different parameters, such as signs/symptoms, development of COVID Pneumonia, intensive care unit (ICU) admission, mechanical ventilation mechanical ventilation, and death. Secondly, maternal outcomes in terms of termination of pregnancy/mode of delivery and complications in COVID-19-positive patients were assessed. Maternal outcomes included were abortions, pre-term birth, premature rupture of membrane (PROM), caesarean section (CS) delivery and pregnancy-related complications. Finally, foetal outcomes, like abortions, intrauterine fetal death (IUFD), pre-term birth, perinatal and neonatal deaths, were assessed. The perinatal outcomes included were Appearance, Pulse, Grimace, Activity and Respiration (APGAR) score (1 and 5 minutes), foetal distress, asphyxia, perinatal death (stillbirth or neonatal death), development of pneumonia due to COVID-19, admission of newborn to neonatal intensive care unit (NICU), mechanical ventilation required, and death. Maternal COVID-19 symptoms at presentation and symptoms of RT-PCR and/or Immunoglobulin M (IgM) COVID-19-positive newborns at birth were also recorded.
Data was analysed using SPSS 20. For calculation of pooled proportions, MedCalc version 16.4.3 was used.
Of the 8 studies reviewed, 4(50%)17-20 were retrospective, 2(25%)21,22 were case series and 2(25%)23,24 were case reports. Together, the studies had 181 pregnant women. In some studies some pieces of information were missing, and the review reported them as "not reported" (Table-1).
Detail of maternal and foetal outcomes were noted (Table-3).
The age range of 181 pregnant women in the 8 studies was 22-41 years. Gestational age at the onset of COVID-19 symptoms ranged 25-39 weeks. There were 155(85.6%) newborns who survived, besides, there was 1(0.55%) case each of spontaneous abortion, stillbirth, and neonatal death due to asphyxia. Till the end of the respective studies, 17(9.4%) women were still pregnant, while foetal outcome of 6(3.3%) pregnant women was not reported.
Out of 7(4.3%) COVID-19-positive newborns, 2(28.6%) had fever, 2(28.6%) developed dyspnoea, 1(14.3%) had asphyxia, 1(14.3%) developed respiratory distress syndrome (RDS), 1(14.3%) had cyanosis, 3(43%) developed COVID-19 pneumonia, 2(28.6%) required mechanical ventilation and 4(57.2%) got admitted to NICU. Information regarding APGAR score was available for only 5(3%) newborns. APGAR score of 1(20%) neonate was 3 and 4 at 1 and 5 minutes, respectively. APGAR score of another 1(20%) neonate was 6 at 1 minute and 8 at 5 minutes. The rest of the neonates had AGAR scores ranging 8-10.
The most common indication reported for CS delivery was COVID-19 pneumonia 45(46%), followed by previous CS 17(19%) and foetal distress 14(13%) (Table-5).